AbbVie completes $8.0 billion notes offering to support Apogee Therapeutics acquisition
AbbVie Inc. recently completed a $8.0 billion offering of senior notes to support its acquisition of Apogee Therapeutics, Inc. The funds raised will be used to cover the cash portion of the acquisition, as well as related fees and expenses. The remaining proceeds will be allocated for general corporate purposes. This offering brings AbbVie's total debt to approximately $78.9 billion.
Written by urgent.news from Investing.com's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
